Physician profile
Benjamin D Spirn
NPI 1417941592
$2,868.94
in general payments reported to CMS, 2019-2025
19 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $307 · 2021: $550 · 2022: $434 · 2023: $470 · 2024: $634 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $624.95 | 2022-2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $407.41 | 2021-2025 | Tecnis Iol |
| Inspire Medical Systems, INC. | $360.87 | 2023-2025 | Inspire |
| Genentech USA, INC. | $307.19 | 2021-2025 | Vabysmo, Lucentis |
| Glaukos Corporation | $286.66 | 2020-2021 | |
| Allergan, INC. | $174.34 | 2020-2021 | |
| Sight Sciences, INC. | $140.31 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $85.46 | 2020-2024 | Eylea |
| Biogen, INC. | $73.26 | 2023-2024 | Byooviz |
| Coherus Oncology, INC. | $65.36 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $60.76 | 2023-2025 | Miebo, Xiidra, Infuse |
| Sandoz INC. | $53.75 | 2024-2025 | Cimerli |
| Astellas Pharma US INC | $52.03 | 2025 | Izervay |
| Abbvie INC. | $51.73 | 2023-2025 | Ozurdex |
| Alimera Sciences, INC. | $39.39 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $36.10 | 2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $19.00 | 2025 | |
| Mallinckrodt Hospital Products INC. | $15.39 | 2024 | Acthar |
| Dompe US, INC. | $14.98 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Spirn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.